IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the publication of its 2023 Ethos and Sustainability Report. The report highlights Inari’s commitment to its ethos and important corresponding environmental, social and governance (ESG) initiatives. The report can be found on Inari’s website here.
Financial
Nectero Medical Announces Completion of $96M Series D Financing
TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round. Financing was led by Norwest Venture Partners, with large investments from Boston Scientific Corporation, BioStar Capital, Cadence Healthcare Ventures, Aphelion Capital and other firms. […]
Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024
SUNNYVALE, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Cathie Biga is New American College of Cardiology President
Biga makes history as the global cardiovascular organization’s first non-physician president ATLANTA, April 8, 2024 /PRNewswire/ — Cathie Biga, MSN, FACC, today became president of the American College of Cardiology and made history as the organization’s first non-physician president….
Rebound Medical Receives Growth Equity Investment from Castleford Capital
Investment supports Rebound Medical’s DME services for orthopedic and vascular physician practices DANBURY, Conn., April 8, 2024 /PRNewswire/ — Castleford Capital (“Castleford”), a private equity firm focused on investing in healthcare and pharmaceutical services companies, today…
New Health Economic Analysis Presented at ACC Highlights the Acarix CADScor System’s Cost-Effectiveness
NEW YORK, April 8, 2024 /PRNewswire/ — Acarix, a leader in acoustic-based Cardiac Diagnostics, is pleased to announce the results from a 2024 American College of Cardiology (ACC) poster presentation by Suzanne Baron, MD, MSc, Director of Interventional Cardiology Research, Massachusetts…
Johnson & Johnson to Acquire Shockwave Medical
April 05, 2024 06:31 AM Eastern Daylight Time NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 […]
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO): “During our fiscal third quarter, we took another significant step in our transformation with the divestiture of our PICC and Midline product portfolios, further strengthening our balance sheet and providing us with an opportunity to enhance our focus on the growth of our Med […]
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a strategic partnership with Navierre, an innovative digital health technology platform which revolutionizes how patients access healthcare and serves as a true health companion for every stage from birth to the golden years with a robust care […]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. These grants were made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).



